• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·IAGX
Share

Imagenetix, Inc. Stocks

$ 0Last Updated 22.10.2026

Issuer Rating

Performance

Strong

Risk

High

Recommendation

Sell

Market Cap

$ 5685

$ 0
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Established in 1996 and headquartered in San Diego, California, Imagenetix, Inc. focuses on the creation, manufacturing, and distribution of distinctive, natural-ingredient nutritional supplements, as well as non-prescription topical creams and skincare solutions. Its flagship product, Celadrin, is a specialized formulation aimed at promoting joint well-being. The company also extends its business by licensing its proprietary technologies to third parties. Imagenetix reaches its customer base through a wide range of marketing avenues, encompassing direct and large-scale marketing enterprises, health and nutritional periodicals, medical and wellness professionals, and direct-response campaigns across radio and television.

Company Valuation

Greatly undervalued
7/7

Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

23.10.2026 15:26

Morning in New York: Capital Rotation Faces the PMI Test

23.10.2026 15:00

Lycia IPO: Shares in the biotech company founded by a Nobel laureate are now available

23.10.2026 14:51

Why Central Asian Companies Are in No Hurry to Go Public. And Is It Necessary?

23.10.2026 14:02

Gucci's parent company's stock plummeted by more than 10% due to a decline in sales

23.10.2026 13:03

The price of Brent crude oil exceeded $114 for the first time since May

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026